Multiple sclerosis drug helps coronavirus patients recover, Phase 2 trial suggests

A drug normally prescribed to treat multiple sclerosis helped reduce the risk of severe disease from Covid-19, British researchers reported Thursday.

Posted: Nov 12, 2020 6:17 PM
Updated: Nov 12, 2020 6:18 PM

A drug normally prescribed to treat multiple sclerosis helped reduce the risk of severe disease from Covid-19, British researchers reported Thursday. But more research is needed to show whether the drug, which calms down the immune system, can really help people with severe coronavirus infections.

The researchers found British biotechnology company Synairgen's new experimental version of interferon beta-1a, repurposed to treat Covid-19, increased the odds of improvement and recovery among hospitalized Covid-19 patients in a Phase 2 trial.

"SNG001 reduced the odds of developing severe disease or dying by 79%," the researchers wrote in the journal The Lancet Respiratory Medicine.

SNG001 is an inhaled formula of interferon beta-1a, typically used to decrease inflammation and reduce the nerve damage caused by multiple sclerosis. In the trial, SNG001 was administered to 48 patients using a nebulizer while 50 patients received the placebo.

After two weeks, patients who got the daily treatment were twice as likely to get better by day 15 or 16 and more than three times as likely to improve by day 28 than those who got placebo, the researchers found. However, "there was no significant difference between treatment groups in the odds of hospital discharge or time to hospital discharge," the researchers wrote.

The researchers, from Synairgen and other institutions, found that during the two weeks of treatment, 21 patients -- or 44% -- in the SNG001 group recovered from disease compared with 11 patients -- or 22% -- in the placebo group. Then by the 28th day, 58% in the SNG001 group had recovered compared with 35% in the placebo group.

Overall, three patients died during the study and all were in the placebo group.

The researchers also found that 11 patients -- or 22% -- in the placebo group developed severe disease by day 16 compared with six patients -- or 13% -- in the SNG001 group.

The most common adverse event in the SNG001 group was headache.

"SNG001, a treatment already studied and shown to be well tolerated in patients with asthma and COPD, seems to also be well tolerated in patients admitted to hospital with COVID-19," the researchers wrote in the study. "These encouraging data provide a strong rationale for larger, international studies in the context of the ongoing clinical burden of COVID-19."

The study comes with limitations, including that the number of patients in the study was small.

'There would need to be a Phase 3 trial'

"There seems to be possibly a signal here, but it's unclear how much of a signal. There's not evidence that it's a dramatic signal, like a mortality signal necessarily, and it's a small study. I think the authors of the paper sum it up best when they say there would need to be a Phase 3 trial," said Dr. Jay Finigan, pulmonologist and director of The Respiratory Centers of Excellence at National Jewish Health in Denver, who was not involved in the new study.

"All in all, we're talking relatively small numbers and there is not a signal in terms of things like discharge or mortality, although it is certainly not powered for that," he said.

Currently, the drug remdesivir is the only treatment approved by the US Food and Drug Administration for Covid-19. Some other therapies -- Eli Lilly's antibody treatment and convalescent plasma -- have received emergency use authorizations for the treatment of Covid-19. Additionally, several experimental treatments are currently being studied.

"There are certainly lots of different drugs with different delivery mechanisms. There are other inhaled drugs that are being thought about and looked at and they target different areas," Finigan said.

"There are antiviral drugs, there are drugs acting on the immune system, antibodies, there are drugs that are trying to target inflammation and some of the inflammatory mediators," he said. "All in all, unfortunately the data that have come out in this population of patients have been pretty largely consistent in that none of them have shown a mortality benefit with the exception of dexamethasone," a corticosteroid.

When it comes to SNG001, "larger randomized clinical trials" are needed, Nathan Peiffer-Smadja and Yazdan Yazdanpanah, both of Bichat-Claude Bernard Hospital in Paris, wrote in an editorial that published alongside the new study in The Lancet Respiratory Medicine.

"The safety of nebulized interferon beta-1a will be of special interest since nebulization of interferon has no marketing authorization for any indication yet," Peiffer-Smadja and Yazdanpanah wrote.

"It will also be worthwhile to investigate whether interferon beta-1a has an impact on prolonged symptoms of COVID-19, especially pulmonary symptoms," they wrote. "To optimize the antiviral effect of interferon beta, there is a greater rationale to target patients at an early stage of the disease."

Oregon Coronavirus Cases

Data is updated nightly.

Cases: 175121

Reported Deaths: 2460
CountyCasesDeaths
Multnomah34937568
Washington23491229
Marion20195299
Clackamas15386204
Lane11591144
Jackson9923127
Umatilla796883
Deschutes712972
Linn416063
Yamhill410175
Klamath349059
Polk344252
Malheur342858
Josephine306362
Douglas304765
Benton273218
Jefferson207032
Coos197531
Columbia154526
Union141624
Lincoln130220
Wasco129128
Hood River112529
Morrow107915
Clatsop8958
Crook88019
Baker85814
Curry5959
Tillamook5813
Lake4137
Grant4124
Harney3066
Wallowa1575
Sherman570
Gilliam561
Wheeler251
Unassigned00

California Coronavirus Cases

Data is updated nightly.

Cases: 3718210

Reported Deaths: 61038
CountyCasesDeaths
Los Angeles122899723653
Riverside2972154525
San Bernardino2947794555
San Diego2749603674
Orange2689624896
Santa Clara1170812013
Kern1078591322
Sacramento1011721646
Fresno1005621646
Alameda853671477
Ventura802301000
San Joaquin714311334
Contra Costa67019782
Stanislaus603831028
Tulare49383829
Monterey43267357
San Mateo41157560
San Francisco36032523
Santa Barbara33896446
Solano31875239
Merced31196452
Sonoma29696311
Imperial27987719
Kings22774245
Placer21751283
San Luis Obispo20917256
Madera16260239
Santa Cruz15571204
Marin13861226
Yolo13580200
Shasta11677217
Butte11573196
El Dorado9719109
Napa966679
Sutter9268109
Yuba609844
San Benito598663
Lassen566924
Tehama543056
Nevada445775
Tuolumne406664
Mendocino398747
Amador362551
Humboldt358737
Lake340943
Glenn235725
Colusa219816
Calaveras205551
Siskiyou194021
Inyo141738
Del Norte12747
Mono12734
Plumas6906
Modoc4884
Mariposa4247
Trinity3985
Sierra1100
Alpine880
Unassigned610
Medford
Partly Cloudy
58° wxIcon
Hi: 75° Lo: 42°
Feels Like: 58°
Brookings
Partly Cloudy
46° wxIcon
Hi: 65° Lo: 46°
Feels Like: 46°
Medford
Mostly Cloudy
58° wxIcon
Hi: 54° Lo: 30°
Feels Like: 58°
Medford
Partly Cloudy
58° wxIcon
Hi: 77° Lo: 42°
Feels Like: 58°
Klamath Falls
Cloudy
52° wxIcon
Hi: 67° Lo: 37°
Feels Like: 52°
Shower chances later tonight
KDRV Radar
KDRV Fire Danger
KDRV Weather Cam

Community Events